Assessment and management of agitation in psychiatry: Expert consensus

World Journal of Biological Psychiatry

Volumn 17, Issue 2, 2016, Pages 86-128

  Garriga, Marina ^a   Pacchiarotti, Isabella ^a   Kasper, Siegfried ^b   Zeller, Scott L ^c   Allen, Michael H ^d   Vázquez, Gustavo ^e   Baldacąra, Leonardo ^f   San, Luis ^g   McAllister Williams, R Hamish ^h   Fountoulakis, Konstantinos N ⁱ   Courtet, Philippe ^j   Naber, Dieter ^k   Chan, Esther W ^l   Fagiolini, Andrea ^m   Möller, Hans Jürgen ⁿ   Grunze, Heinz ^o   Llorca, Pierre Michel ^p   Jaffe, Richard L ^q   Yatham, Lakshmi N ^r   Hidalgo Mazzei, Diego ^a   Passamar, Marc ^s   Messer, Thomas ^t   Bernardo, Miquel ^a   Vieta, Eduard ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Alameda Health System   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF PALERMO   (Argentina)

^f UNIVERSIDADE FEDERAL DO TOCANTINS   (Brazil)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^j LAPEYRONIE HOSPITAL   (France)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY OF HONG KONG   (Hong Kong)

^m UNIVERSITY OF SIENA   (Italy)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o PARACELSUS MEDICAL UNIVERSITY   (Austria)

^p UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^q Belmont Behavioral Hospital   (United States)

^r UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^s SAUS   (France)

^t Danuvius Klinik   (Germany)

more..

Author keywords

Agitation; assessment; psychiatric emergency; restraint; verbal de escalation

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGGRESSION; ARTICLE; BEHAVIOURAL ACTIVITY RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COHEN MANSFIELD AGITATION INVENTORY; DELPHI STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; MENTAL DISEASE; NONHUMAN; OVERT AGGRESSION SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREGNANCY; PSYCHIATRY; RESTLESSNESS; STAFF OBSERVATION AGGRESSION SCALE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; VIOLENCE; CONSENSUS; DISEASE MANAGEMENT; EMERGENCY HEALTH SERVICE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONSENSUS; DISEASE MANAGEMENT; EMERGENCY MEDICAL SERVICES; HUMANS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHIATRY; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84959259565     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2015.1132007     Document Type: Article

References (221)

1. Agid O, Kapur S, Warrington L, Loebel A, Siu C. 2008. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res. 102: 241-248 http://www.ncbi.nlm.nih.gov/pubmed/18495436
2. Alexander J. 2004. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatr. 185: 63-69 http://bjp.rcpsych.org/cgi/doi/10.1192/bjp.185.1.63
3. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. 2005. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med. 6-22.
4. Alexopoulos GS, Silver JM, Kahn DA, et al. 1998. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia. Postgrad Med. 1-88.
5. Allen MH, Currier GW. 2004. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatr. 26: 42-49 http://www.ncbi.nlm.nih.gov/pubmed/14757302
6. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. 2005. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 11 (Suppl 1): 5-108. quiz 110-112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16319571
7. Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R. 2003. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract. 9: 16-3 http://www.ncbi.nlm.nih.gov/pubmed/15985913
8. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. 2001. The Expert Consensus guideline series. Treatment of behavioral emergencies. Postgrad Med. 1-88. quiz 89-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11500996
9. Allen MH, Debanné M, Lazignac C, Adam E, Dickinson LM, Damsa C. 2011a. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatr. 168: 395-399.
10. Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al. 2011b. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatr. 72: 1313-1321.
11. Almvik R, Woods P. 1999. Predicting inpatient violence using the Broset Violence Checklist (BVC). Int J Psychiatr Nurs Res. 4: 498-505 http://www.ncbi.nlm.nih.gov/pubmed/10451308
12. APA (American Psychiatric Association). 1987. Diagnostic and statistical manual on mental disorders, third edition-revised. Washington (DC): American Psychiatric Publishing.
13. APA (American Psychiatric Association). 2013. Diagnostic and statistical manual of mental disorders, 5th edition. Washington (DC): American Psychiatric Publishing. Available from: http://dsm.psychiatryonline.org//book.aspx?doi=10.1176/appi.books.9780890425596.893619
14. Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al. 2006a. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 106: 281-292 http://www.ncbi.nlm.nih.gov/pubmed/16953381
15. Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, et al. 2006b. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin. 22: 2209-221 http://www.ncbi.nlm.nih.gov/pubmed/17076982
16. Angermeyer MC. 2000. Schizophrenia and violence. Acta Psychiatr Scand. Suppl: 63-67.
17. Angst J, Gamma A, Benazzi F, Ajdacic V, Rössler W. 2009. Does psychomotor agitation in major depressive episodes indicate bipolarity? Evidence from the Zurich Study. Eur Arch Psychiatr Clin Neurosci. 259: 55107 http://www.ncbi.nlm.nih.gov/pubmed/18806921
18. Arvanitis LA, Miller BG. 1997. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 42: 233-24 http://www.ncbi.nlm.nih.gov/pubmed/9270900
19. Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A, et al. 2015. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation. Int Clin Psychopharmacol. 30: 142-150 http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004850-201505000-00003
20. Baker SN. Management of acute agitation in the emergency department. Adv Emerg Nurs J. 34: 306-18; quiz 319-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23111305
21. Baker RW, Kinon BJ, Maguire Ga, Liu H, Hill AL. 2003. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol. 23: 342-348 http://www.ncbi.nlm.nih.gov/pubmed/12920409
22. Balázs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. 2006. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 91: 133-138 http://www.ncbi.nlm.nih.gov/pubmed/16458364
23. Baldacąra L, Sanches M, Cordeiro DC, Jackoswski AP. 2011. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Rev Bras Psiquiatr. 33: 30-39 http://www.ncbi.nlm.nih.gov/pubmed/21537720
24. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. 1997. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 15: 335-340 http://www.ncbi.nlm.nih.gov/pubmed/9217519
25. Battaglia J. 2005. Pharmacological management of acute agitation. Drugs. 65: 1207-1222 http://www.ncbi.nlm.nih.gov/pubmed/15916448
26. Bieniek SA, Ownby RL, Penalver A, Dominguez RA. 1998. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy. 18: 57-62 http://www.ncbi.nlm.nih.gov/pubmed/9469682
27. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. 2005. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatr. 66: 111-121.
28. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. 2002. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychitr. 59: 441-448 http://archpsyc.jamanetwork.com/article.aspx?articleid=206340
29. Brook S, Lucey JV, Gunn KP. 2000. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatr. 61: 933-941 http://www.ncbi.nlm.nih.gov/pubmed/11206599
30. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. 2005. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 178: 514-523 http://www.ncbi.nlm.nih.gov/pubmed/15650846
31. Bryan CJ, Hitschfeld MJ, Palmer BA, Schak KM, Roberge EM, Lineberry TW. 2014. Gender differences in the association of agitation and suicide attempts among psychiatric inpatients. Gen Hosp Psychiatr. 36: 726-731 http://www.ncbi.nlm.nih.gov/pubmed/25312276
32. Buchanan A, Leese M. 2001. Detention of people with dangerous severe personality disorders: a systematic review. Lancet 358: 1955-1959 http://www.ncbi.nlm.nih.gov/pubmed/11747920
33. Castle DJ, Udristoiu T, Kim CY, Sarosi A, Pidrman V, Omar AN, et al. 2009. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatr. 10: 43-53 http://www.ncbi.nlm.nih.gov/pubmed/19137460
34. Chan EW, Taylor DM, Knott JC, Kong DCM. 2011. Variation in the management of hypothetical cases of acute agitation in Australasian emergency departments. Emerg Med Australas. 23: 23120 http://www.ncbi.nlm.nih.gov/pubmed/21091874
35. Chan EW, Taylor DM, Knott JC, Phillips GA, Castle DJ, Kong DCM. 2013. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 61: 72-81.
36. Chan H-Y, Ree S-C, Su L-W, Chen J-J, Chou S-Y, Chen C-K, et al. 2014. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. J Clin Psychopharmacol. 34: 355-358 http://www.ncbi.nlm.nih.gov/pubmed/24743717
37. Chandrasena R, Dvoráková D, Lee SI, Loza N, Mosolov SN, Osváth P, et al. 2009. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Int J Clin Pract. 63: 1249-1258 http://www.ncbi.nlm.nih.gov/pubmed/19558486
38. Chaput Y, Beaulieu L, Paradis M, Labonté E. 2011. The elderly in the psychiatric emergency service (PES); a descriptive study. BMC Psychiatr. 11: 111
39. Chengappa KNR, Goldstein JM, Greenwood M, John V, Levine J. 2003. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 25: 530-541 http://www.ncbi.nlm.nih.gov/pubmed/12749512
40. Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N. 1993. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatr. 38 (Suppl 4): S114-S121 http://www.ncbi.nlm.nih.gov/pubmed/8306241
41. Citrome L. 2002. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med. 112: 85-88. 94-6 http://www.ncbi.nlm.nih.gov/pubmed/12510449
42. Citrome L. 2004. New treatments for agitation. Psychiatr Q. 75: 197-213http://www.ncbi.nlm.nih.gov/pubmed/15335224
43. Citrome L. 2012. Inhaled loxapine for agitation revisited: Focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract. 66: 318-325.
44. Citrome L, Volavka J. 2014. The psychopharmacology of violence: making sensible decisions. CNS Spectr. 19: 411-418 http://www.ncbi.nlm.nih.gov/pubmed/24571828
45. Cohen-Mansfield J, Werner P, Marx MS. 1989. An observational study of agitation in agitated nursing home residents. Int Psychogeriatr. 1: 153-165 http://www.ncbi.nlm.nih.gov/pubmed/2491142
46. Cooper SJ, Browne FW, McClean KJ, King DJ. 1983. Aggressive behaviour in a psychiatric observation ward. Acta Psychiatr Scand. 68: 386-393 http://www.ncbi.nlm.nih.gov/pubmed/6650217
47. Cornaggia CM, Beghi M, Pavone F, Barale F. 2011. Aggression in psychiatry wards: A systematic review. Psychiatr Res. 189: 10-2 http://www.ncbi.nlm.nih.gov/pubmed/21236497
48. Currier GW, Allen MH, Bunney EB, Daniel DG, Francis A, Jagoda A, et al. 2004. Standard therapies for acute agitation. J Emerg Med. 27: S9-12. quiz S7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15504618
49. Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, et al. 2007. Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract. 13: 159-169 http://www.ncbi.nlm.nih.gov/pubmed/17522559
50. Currier GW, Medori R. 2006. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract. 12: 30-4 http://www.ncbi.nlm.nih.gov/pubmed/16432443
51. Currier GW, Simpson GM. 2001. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatr. 62: 153-157 http://www.ncbi.nlm.nih.gov/pubmed/11305699
52. DOnofrio G, Jauch E, Jagoda A, Allen MH, Anglin D, Barsan WG, et al. 2010. NIH roundtable on opportunities to advance research on neurologic and psychiatric emergencies. Ann Emerg Med. 56: 551-564.
53. Dack C, Ross J, Papadopoulos C, Stewart D, Bowers L. 2013. A review and meta-analysis of the patient factors associated with psychiatric in-patient aggression. Acta Psychiatr Scand. 127: 255-268 http://www.ncbi.nlm.nih.gov/pubmed/23289890
54. Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, et al. 2007. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract. 13: 170-177 http://www.ncbi.nlm.nih.gov/pubmed/17522560
55. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. 2001. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 155: 128-134 http://link.springer.com/10.1007/s002130000658
56. Daniel DG, Saha AR, Ingenito GCW,GD. 2000. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract]. Int J Neuropsychopharmacol. 3 (Suppl 1): S157.
57. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, et al. 2013. Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation. Pharmacotherapy. 33: 603-614 http://doi.wiley.com/10.1002/phar.1260
58. Dolan M, Blattner R. 2010. The utility of the Historical Clinical Risk-20 Scale as a predictor of outcomes in decisions to transfer patients from high to lower levels of security-a UK perspective. BMC Psychiatr. 10: 76
59. Donat DC. 2003. An analysis of successful efforts to reduce the use of seclusion and restraint at a public psychiatric hospital. Psychiatr Serv. 54: 1119-1123 http://www.ncbi.nlm.nih.gov/pubmed/12883139
60. Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. 1999. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatr. 156: 142-144.
61. Doyle M, Dolan M. 2006. Predicting community violence from patients discharged from mental health services. Br J Psychiatr. 189: 520-526 http://www.ncbi.nlm.nih.gov/pubmed/17139036
62. Duxbury J, Whittington R. 2005. Causes and management of patient aggression and violence: staff and patient perspectives. J Adv Nurs. 50: 469-478 http://www.ncbi.nlm.nih.gov/pubmed/15882363
63. Escobar R. 2008. Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study. Actas Esp Psiquiatr. 36: 151-157.
64. Fang M, Chen H, Li L-H, Wu R, Li Y, Liu L, et al. 2012. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Int Clin Psychopharmacol. 27: 107-113 http://www.ncbi.nlm.nih.gov/pubmed/22233697
65. Fisher WA. 1994. Restraint and seclusion: a review of the literature. Am J Psychiatry. 151: 1584-1591 http://www.ncbi.nlm.nih.gov/pubmed/7943445
66. Fishkind A. 2002. Calming agitation with words, not drugs: 10 commandments for safety. Curr Psych. 1 (4).
67. Fitzgerald CH. 1969. A double-blind comparison of haloperidol with perphenazine in acute psychiatric episodes. Curr Ther Res Clin Exp. 11: 515-519.
68. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12: 189-198 http://www.ncbi.nlm.nih.gov/pubmed/1202204
69. Ford AH, Almeida OP. 2015. Pharmacological interventions for preventing delirium in the elderly. Maturitas. 81: 287-292 http://www.ncbi.nlm.nih.gov/pubmed/25890587
70. Fountoulakis KN, Leucht S, Kaprinis GS. 2008. Personality disorders and violence. Curr Opin Psychiatr. 21: 84-92 http://www.ncbi.nlm.nih.gov/pubmed/18281846
71. Fresán A, Apiquian R, de la Fuente-Sandoval C, Garciá-Anaya M, Nicolini H. [Sensitivity and specificity of the Overt Aggression Scale in schizophrenic patients]. Actas Espanõlas Psiquiatr. 32: 71-75 http://www.ncbi.nlm.nih.gov/pubmed/15042466
72. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K. 1977. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand. 56: 256-264.
73. Galbally M, Snellen M, Power J. 2014. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf. 5: 100-109 http://taw.sagepub.com/content/5/2/100.abstract
74. Gault TI, Gray SM, Vilke GM, Wilson MP. 2012. Are oral medications effective in the management of acute agitation? J Emerg Med. 43: 854-9 http://www.ncbi.nlm.nih.gov/pubmed/22541877
75. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. 2005. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330: 445. doi:10.1136/bmj.38330.470486.8F
76. Gutheil TG. 1980. Restraint versus treatment: seclusion as discussed in the Boston State Hospital case. Am J Psychiatr 137: 718-719 http://www.ncbi.nlm.nih.gov/pubmed/7377394
77. Hankin C, Bronstone A, Koran L. 2011. Agitation in the inpatient psychiatric setting: A Review of Clinical Presentation, Burden, and Treatment. J Psychiatr. 17: 170-185 http://www.ncbi.nlm.nih.gov/pubmed/21586995
78. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. 2012. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatr. 13: 318-378.
79. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, et al. 2008. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatr. 30: 367-371 http://www.ncbi.nlm.nih.gov/pubmed/18585542
80. Herrera JN, Sramek JJ, Costa JF, Roy S, Heh CW, Nguyen BN. 1988. High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis. 176: 558-561 http://www.ncbi.nlm.nih.gov/pubmed/3418329
81. Higashima M, Takeda T, Nagasawa T, Hirao N, Oka T, Nakamura M, et al. 2004. Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. Eur Psychiatr. 19: 380-381 http://www.ncbi.nlm.nih.gov/pubmed/15363480
82. Hill S, Petit J. 2000. The violent patient. Emerg Med Clin North Am. 18: 301-315 http://www.ncbi.nlm.nih.gov/pubmed/10767886
83. Holloman GH, Zeller SL. 2012. Overview of Project BETA: Best practices in evaluation and treatment of agitation. West J Emerg Med. 13: 1-2. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298232&tool=pmcentrez&rendertype=abstract
84. Hsu W-Y, Huang S-S, Lee B-S, Chiu N-Y. 2010. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol. 30: 230-234. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20473056
85. Huber CG, Lambert M, Naber D, Schacht A, Hundemer H-P, Wagner TT, et al. 2008. Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophr Res. 100: 342-348. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18255271
86. Huf G, Alexander J, Allen MH. 2005. Haloperidol plus promethazine for psychosis induced aggression. Cochrane Database Syst Rev. 1: CD005146 http://www.ncbi.nlm.nih.gov/pubmed/15654706
87. Huf G, Coutinho ESF, Adams CE, TREC-Rio trial. 2002. TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. BMC Psychiatr. 2: 11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12383353
88. Huf G, Coutinho ESF, Adams CE. 2007. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 335: 869 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2043463&tool=pmcentrez&rendertype=abstract
89. Hughes DH. 1996. Suicide and violence assessment in psychiatry. Gen Hosp Psychiatr. 18: 416-421. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8937907
90. Ilkiw-Lavalle O, Grenyer BFS. 2003. Differences between patient and staff perceptions of aggression in mental health units. Psychiatr Serv. 54: 389-393. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12610249
91. Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. 2010. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med. 56: 392-401.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20868907
92. Iwanami T, Maeshima H, Baba H, Satomura E, Namekawa Y, Shimano T, et al. 2014. Psychomotor agitation in major depressive disorder is a predictive factor of mood-switching. J Affect Disord. 170: 185-189. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25248024
93. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17: 1-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8721797
94. Jarema M.R. 2015. Leczenie pacjentów pobudzonych. In: Medica V., editor. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Gdańsk. pp. 49-51.
95. Jones J, Hunter D. 1995. Consensus methods for medical and health services research. BMJ 311: 376-380. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2550437&tool=pmcentrez&rendertype=abstract
96. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. 2002. Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder. J Clin Psychiatry 63: 763-771.
97. Kasper S, Baranyi A, Eisenburger P, Erfurth A, Ertl M, Frey R, et al. 2013. Die Behandlung der Agitation beim psychiatrischen Notfall. Konsensus-Statement-State of the art 2013. Clin Neuropsy Sonderausgabe.
98. Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, et al. 2013. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatr. 13: 20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23311957
99. Kaufman DM, Zun L. 1995. A quantifiable, brief mental status examination for emergency patients. J Emerg Med. 13: 449-456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7594361
100. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13: 261-276. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3616518
101. Kinon BJ, Ahl J, Rotelli MD, McMullen E. 2004. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med. 22: 181-186. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15138953
102. Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. 2001. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatr. 62 (Suppl 2): 17-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11232746
103. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. 2008. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. 28: 601-607. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19011427
104. Knott JC, Taylor DM, Castle DJ. 2006. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med. 47: 61-67.
105. Knox DK, Holloman GH. 2012. Use and avoidance of seclusion and restraint: consensus statement of the american association for emergency psychiatry project Beta seclusion and restraint workgroup. West J Emerg Med. 13: 35-40. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298214&tool=pmcentrez&rendertype=abstract
106. Kopecky HJ, Kopecky CR, Yudofsky SC. 1998. Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients. Psychiatr Q. 69: 301-323. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9793109
107. Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, et al. 2012. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 14: 31-40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22329470
108. Ladavac AS, Dubin WR, Ning A, Stuckeman PA. 2007. Emergency management of agitation in pregnancy. Gen Hosp Psychiatr. 29: 39-41.
109. Långström N, Grann M, Ruchkin V, Sjöstedt G, Fazel S. 2009. Risk factors for violent offending in autism spectrum disorder: a national study of hospitalized individuals. J Interpers Violence 24: 1358-1370. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18701743
110. Lee HK, Villar O, Juthani N, Bluestone H. 1989. Characteristics and behavior of patients involved in psychiatric ward incidents. Hosp Community Psychiatr. 40: 1295-1297. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2591887
111. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. 1992. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatr. 53: 47-52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1541605
112. Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. 2011. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatr. 198: 51-58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21200077
113. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. 2001. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatr. 62: 12-18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11235922
114. Lesser JM, Hughes S. 2006. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimers disease: definitions and treatment options. Geriatrics. 61: 14-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17184138
115. Leung JG, Benedetti AM, Frazee LA, Myers N. 2011. Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. Am J Ther. 18: 300-304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20335789
116. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. 2010. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 62: 81-86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20523078
117. Linaker OM, Busch-Iversen H. 1995. Predictors of imminent violence in psychiatric inpatients. Acta Psychiatr Scand. 92: 250-254. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8848948
118. Lindenmayer JP. 2000. The pathophysiology of agitation. J Clin Psychiatr. 61 (Suppl 1): 5-10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11154018
119. Lindenmayer J-P, Bossie CA, Kujawa M, Zhu Y, Canuso CM. 2008. Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology. 41: 264-270. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18441528
120. Lukens TW, Wolf SJ, Edlow Ja, Shahabuddin S, Allen MH, Currier GW, et al. 2006. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med. 47: 79-99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16387222
121. MacDonald K, Wilson M, Minassian A, Vilke GM, Becker O, Tallian K, et al. 2012. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol. 32: 317-322. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22544013
122. MacDonald K, Wilson MP, Minassian A, Vilke GM, Perez R, Cobb P, et al. 2010. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug-and alcohol-using patients. Gen Hosp Psychiatry. 32: 443-445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20633750
123. Man PL, Chen CH. 1973. Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine.
124. Mantovani C, Labate CM, Sponholz A, de Azevedo Marques JM, Guapo VG, de Simone Brito dos Santos ME, et al. 2013. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol. 33: 306-312. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23609398
125. Marco CA, Vaughan J. 2005. Emergency management of agitation in schizophrenia. Am J Emerg Med. 23: 767-76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16182986
126. Marder SR. 2006. A review of agitation in mental illness: Treatment guidelines and current therapies. J Clin Psychiatry. 67 (Suppl 1): 13-21.
127. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, et al. 2007. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 68: 662-668. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17503974
128. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. 2005. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 12: 1167-1172. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16282517
129. Mautone A, Scarone S., all investigators. 2011. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial. Pharmacopsychiatry. 44: 173-178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21751127
130. McClure JR, Criqui MH, Macera CA, Ji M, Nievergelt CM, Zisook S. 2015. Prevalence of suicidal ideation and other suicide warning signs in veterans attending an urgent care psychiatric clinic. Compr Psychiatry. 60: 149-155. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0010440X14002661
131. McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. 2007. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 41: 895-905.
132. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. 2005. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 15: 573-585.
133. McNiel DE, Binder RL. 1994. The relationship between acute psychiatric symptoms, diagnosis, and short-term risk of violence. Hosp Community Psychiatr. 45: 133-137. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8168791
134. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. 2001. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 21: 389-397. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11476123
135. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 2015. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 4:1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25554246
136. Mohr WK, Petti TA, Mohr BD. 2003. Adverse effects associated with physical restraint. Can J Psychiatr. 48: 330-337. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12866339
137. Montoya A, Valladares A, Lizán L, San L, Escobar R, Paz S. 2011. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcome. 9: 18 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3078838&tool=pmcentrez&rendertype=abstract
138. Nassisi D, Korc B, Hahn S, Bruns J, Jagoda A. 2006. The evaluation and management of the acutely agitated elderly patient. Mt Sinai J Med. 73: 976-984.
139. Ng AT, Zeller SRR. 2010. Clinical challenges in the pharmacologic management of agitation. Prim Psychiatr. 18: 46-52.
140. Nijman HLI, Palmstierna T, Almvik R, Stolker JJ. 2005. Fifteen years of research with the staff observation aggression scale: A review. Acta Psychiatr Scand. 111: 12-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15636589
141. Nobay F, Simon BC, Levitt MA, Dresden GM. 2004. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med. 11: 744-749. Available from: http://doi.wiley.com/10.1197/j.aem.2003.06.015
142. Nordstrom K, Allen MH. 2007. Managing the acutely agitated and psychotic patient. CNS Spectr. 12: 5-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17934384
143. Nordstrom K, Zun LS, Wilson MP, Md VS, Ng AT, Bregman B, et al. 2012. Medical evaluation and triage of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta medical evaluation workgroup. West J Emerg Med. 13: 3-10. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298208&tool=pmcentrez&rendertype=abstract
144. Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. 2006. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry. 39: 209-212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17124642
145. Nourse R, Reade C, Stoltzfus J, Mittal V. 2014. Demographics, clinical characteristics, and treatment of aggressive patients admitted to the acute behavioral unit of a community general hospital: a prospective observational study. Prim Care Companion CNS Disord. 16: ppi http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4195636&tool=pmcentrez&rendertype=abstract
146. Ogloff JRP, Daffern M. 2006. The dynamic appraisal of situational aggression: an instrument to assess risk for imminent aggression in psychiatric inpatients. Behav Sci Law. 24: 799-813. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17171770
147. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. 2013. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatr. 170: 1249-1262. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4091043&tool=pmcentrez&rendertype=abstract
148. Pacchiarotti I, Mazzarini L, Kotzalidis GD, Valentí M, Nivoli AMA, Sani G, et al. 2011. Mania and depression. Mixed, not stirred. J Affect Disord. 133: 105-113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21514674
149. Palmstierna T, Wistedt B. 1987. Staff observation aggression scale, SOAS: presentation and evaluation. Acta Psychiatr Scand. 76: 657-663. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3442256
150. Paprocki JVM. 1977. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp. 21: 80-100.
151. Pascual JC, Madre M, Puigdemont D, Oller S, Corripio I, Diáz A, et al. [A naturalistic study: 100 consecutive episodes of acute agitation in a psychiatric emergency department]. Actas espanõlas Psiquiatr. 34: 239-44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16823684
152. Peiró S, Gómez G, Navarro M, Guadarrama I, Rejas J, Alvarez Diáz A, et al. 2004. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain-Description and associated factors-The Psychosp study. Soc Psychiatry Psychiatr Epidemiol. 39: 507-513.
153. Peisah C, Chan DKY, Mckay R, Kurrle SE, Reutens SG. 2011. Practical guidelines for the acute emergency sedation of the severely agitated older patient. Intern Med J. 41: 651-657.
154. Perrin E, Anand E, Dyachkova Y, Wagner T, Frediani S, Ballerini A. 2012. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania. Eur Psychiatr. 27: 234-239. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20620029
155. Perugi G, Akiskal HS, Micheli C, Toni C, Madaro D. 2001. Clinical characterization of depressive mixed state in bipolar-I patients: Pisa-San Diego collaboration. J Affect Disord. 67: 105-114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11869757
156. Perugi G, Angst J, Azorin J-M, Bowden CL, Mosolov S, Reis J, et al. 2015. Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study. J Clin Psychiatr. 76: e351-e358. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25830457
157. Petit JR. 2005. Management of the acutely violent patient. Psychiatr Clin North Am. 28: 701-711, 710. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16122575
158. Piechniczek-Buczek J. 2006. Psychiatric emergencies in the elderly population. Emerg Med Clin North Am. 24: 467-490. viii. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16584967
159. Pilowsky LS, Ring H, Shine PJ, Battersby M, Lader M. 1992. Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry. 160: 831-835. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1352166
160. Popovic D, Nuss P, Vieta E. 2015. Revisiting loxapine: A systematic review. Ann Gen Psychiatr. 14:15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25859275
161. Popovic D, Vieta E, Azorin J-M, Angst J, Bowden CL, Mosolov S, et al. 2015. Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. Bipolar Disord. 17: 795-803. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26415692
162. Potkin SG, Saha MD, PhD AR, Kujawa MJ, PhD MD, Carson WH., et al., 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatr. 60: 681-690.
163. Powell G, Caan W, Crowe M. 1994. What events precede violent incidents in psychiatric hospitals? Br J Psychiatr. 165: 107-112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7953012
164. Powney MJ, Adams CE, Jones H. 2012. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane database Syst Rev. 11: CD009377 http://www.ncbi.nlm.nih.gov/pubmed/23152276
165. Pratts M, Citrome L, Grant W, Leso L, Opler LA. 2014. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 130: 61-68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24606117
166. Preval H, Klotz SG, Southard R, Francis A. 2005. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatr. 27: 140-144. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15763126
167. Putkonen A, Kuivalainen S, Louheranta O, Repo-Tiihonen E, Ryynänen O-P, Kautiainen H, et al. 2013. Cluster-randomized controlled trial of reducing seclusion and restraint in secured care of men with schizophrenia. Psychiatr Serv. 64: 850-855. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23771480
168. Ramadan M. 2006. Managing psychiatric emergencies. Internet J Emerg Med. 4: Available from: https://ispub.com/IJEM/4/1/13551
169. Raveendran NS, Tharyan P, Alexander J, Adams CE. 2007. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ. 335: 865 http://www.ncbi.nlm.nih.gov/pubmed/10
170. Resnick M, Burton BT. 1984. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatr. 45: 298-299. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6376480
171. Ribeiro JD, Bender TW, Selby Ea, Hames JL, Joiner TE. 2011. Development and validation of a brief self-report measure of agitation: the Brief Agitation Measure. J Pers Assess. 93: 597-604. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21999383
172. Richards JR, Derlet RW, Duncan DR. 1997. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med. 4: 130-135.
173. Richards JR, Derlet RW, Duncan DR. 1998 Chemical restraint for the agitated patient in the emergency department: Lorazepam versus droperidol. J Emerg Med. 16: 567-573.
174. Richmond JS, Berlin JS, Fishkind AB, Holloman GH, Zeller SL, Wilson MP, et al. 2012. Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. West J Emerg Med. 13: 17-25. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298202&tool=pmcentrez&rendertype=abstract
175. Rosen CL, Ratliff AF, Wolfe RE, Branney SW, Roe EJ, Pons PT. 1997. The efficacy of intravenous droperidol in the prehospital setting. J Emerg Med. 15: 13-17.
176. Royal College of Nursing. 2005. Violence. The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. London: Royal College of Nursing.
177. Rubio-Valera M, Luciano JV, Ortiz JM, Salvador-Carulla L, Gracia A, Serrano-Blanco A. 2015. Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence. BMC Psychiatr. 15: 35 Available from: http://www.biomedcentral.com/1471-244X/15/35
178. Sachs GS. 2006. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 67 (Suppl 1): 5-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16965190
179. Sachs G, Chengappa KNR, Suppes T, Mullen JA, Brecher M, Devine NA, et al. 2004. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 6: 213-223.
180. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A, Pultz JA, et al. 2007. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatr. 68: 1377-1383. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17915976
181. Sani G, Tondo L, Koukopoulos A, Reginaldi D, Kotzalidis GD, Koukopoulos AE, et al. 2011. Suicide in a large population of former psychiatric inpatients. Psychiatr Clin Neurosci. 65: 286-295.
182. Schleifer JJ. 2011. Management of acute agitation in psychosis: an evidence-based approach in the USA. Adv Psychiatr Treat. 17: 91-100. Available from: http://apt.rcpsych.org/cgi/doi/10.1192/apt.bp.109.007310
183. Shah A, Evans H, Parkash N. 1998. Evaluation of three aggression/agitation behaviour rating scales for use on an acute admission and assessment psychogeriatric ward. Int J Geriatr Psychiatr. 13: 415-420. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9658278
184. Sheridan M, Henrion R, Robinson L, Baxter V. 1990. Precipitants of violence in a psychiatric inpatient setting. Hosp Community Psychiatr. 41: 776-780. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2365311
185. Shim IH, Woo YS, Jun T-Y, Bahk W-M. 2014. Mixed-state bipolar I and II depression: time to remission and clinical characteristics. J Affect Disord. 152154: 340-346. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24144581
186. Silver JM, Yudofsky SC. 1991. The Overt Aggression Scale: Overview and guiding principles. J Neuropsychiatry Clin Neurosci. 3: S22-S29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1821217
187. Soyka M. 2002. Aggression in schizophrenia: assessment and prevalence. Br J Psychiatr. 180: 278-279. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11872524
188. Stabenau JR, Grinols DR. 1964. A double-blind comparison of thioridazine and chlorpromazine. Psychiatr Q. 38: 42-63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14148394
189. Stevenson S, Otto MP. 1998. Finding ways to reduce violence in psychiatric hospitals. J Healthc Qual. 20: 28-32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10181903
190. Stotsky BA. 1977. Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Dis Nerv Syst. 38: 967-973.
191. Stowell KR, Florence P, Harman HJ, Glick RL. 2012. Psychiatric evaluation of the agitated patient: consensus statement of the American association for emergency psychiatry project Beta Psychiatric Evaluation Workgroup. West J Emerg Med. 13: 11-16. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298217&tool=pmcentrez&rendertype=abstract
192. Strout TD. 2014. Psychometric testing of the Agitation Severity Scale for acute presentation behavioral management patients in the emergency department. Adv Emerg Nurs J. 36: 250-270. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25076401
193. Suzuki H, Gen K, Takahashi Y. 2014. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol. 29: 83-88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24424709
194. Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. 1998. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 36: 87-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11777497
195. Taymeeyapradit U, Kuasirikul S. 2002. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. J Med Assoc Thail. 85: 1301-1308.
196. The Joint Commission. 2000. Joint Commission on Accreditation of Healthcare Organizations: Getting a handle on restraint: New behavioural health care stardards spell out specifics of training. Jt Comm Benchmark 2: 1-3.
197. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. 2007. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatr. 68: 111-119. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17284138
198. TREC Collaborative Group. 2003. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ. 327: 708-713. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=200800&tool=pmcentrez&rendertype=abstract
199. Tuason VB. 1986. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatr. 47: 126-129.
200. Veser FH, Veser BD, McMullan JT, Zealberg J, Currier GW. 2006. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. J Psychiatr Pract. 12: 103-108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16728906
201. Vieta E. 2005. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol. 20: 225-236. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15880391
202. Vieta E, Grunze H, Azorin J-M, Fagiolini A. 2014. Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. J Affect Disord. 156: 206-213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24439831
203. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. 2005. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 21: 923-934. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15969892
204. Vieta E, Valentí M. 2013. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 27: 515-529. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23749421
205. Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. 2008. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatr. 32: 405-413. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17900775
206. Walther S, Moggi F, Horn H, Moskvitin K, Abderhalden C, Maier N, et al. 2014. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. J Clin Psychopharmacol. 34: 124-128. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24346752
207. Warnke I, Rössler W, Herwig U. 2011. Does psychopathology at admission predict the length of inpatient stay in psychiatry? Implications for financing psychiatric services. BMC Psychiatr. 11: 120
208. Warren RE, Deary IJ, Frier BM. 2003. The symptoms of hyperglycaemia in people with insulin-treated diabetes: classification using principal components analysis. Diabetes Metab Res Rev. 19: 408-414. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12951649
209. Webster, CD, Douglas, KS, Eaves, D, Hart S. 1997. HCR-20: Assessing risk for violence (Version 2). (Mental Health, Law, & Policy Institute SFU, editor.) Vancouver, Canada: MHLPI.
210. Wilhelm S, Schacht A, Wagner T. 2008. Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial. BMC Psychiatr. 8: 61 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2507712&tool=pmcentrez&rendertype=abstract
211. Wilson MP, Pepper D, Currier GW, Holloman GH, Feifel D. 2012. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 13: 26-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22461918
212. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. 2001. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatr. 158: 1149-1151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11431240
213. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. 2003. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatr. 182: 141-147.
214. Yatham LN, Paulsson B, Mullen J, Vågerö M. 2004. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 24: 599-606. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004714-200412000-00004
215. Yildiz A, Sachs GS, Turgay A. 2003. Pharmacological management of agitation in emergency settings. Emerg Med J. 20: 339-346.
216. Yudofsky SC, Kopecky HJ, Kunik M, Silver JM, Endicott J. 1997. The Overt Agitation Severity Scale for the objective rating of agitation. J Neuropsychiatry Clin Neurosci. 9: 541-548. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9447494
217. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. 1986. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatr. 143: 35-39. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3942284
218. Zeller SL, Rhoades RW. 2010. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 32: 403-425. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20399981
219. Zeller SL. 2010. Treatment of psychiatric patients in emergency settings. Prim Psychiatr. 17: 35-41.
220. Zhang H, Wang G, Zhao J, Xie S, Xu X, Shi J, et al. 2013. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. J Clin Psychopharmacol. 33: 178-185. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23422376
221. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al. 2007. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 27: 171-176. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17414241